# A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage

Study · id `cardio:ct-nct06255977` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06255977](<https://clinicaltrials.gov/study/NCT06255977>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06255977

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT06255977. Randomized; quadruple masking; primary purpose treatment. Start 2022-08-24 (actual); primary completion 2024-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT06255977, source copy `cardio:ctgov-nct06255977-2024-02-13`, retrieved 2026-10-31)
- Started: 2022-08-24 (actual) (ClinicalTrials.gov record NCT06255977, source copy `cardio:ctgov-nct06255977-2024-02-13`, retrieved 2026-10-31)
- Primary completion: 2024-05 (anticipated) (ClinicalTrials.gov record NCT06255977, source copy `cardio:ctgov-nct06255977-2024-02-13`, retrieved 2026-10-31)
- Completion: 2024-08 (anticipated) (ClinicalTrials.gov record NCT06255977, source copy `cardio:ctgov-nct06255977-2024-02-13`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06255977, source copy `cardio:ctgov-nct06255977-2024-02-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06255977-2024-02-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage
- Condition: Intracerebral Hemorrhage
- Intervention (Drug): CN-105
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER
- Collaborator: SDM Bio Service Inc.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 4d25f2ecfb3258d0ab7702d42fefa6dc43ae03dd2c0e198b47549462c4cded3b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
